Biomedicine & Pharmacotherapy · 2024 · 23 citations · 192 references
MedicineCancer BiologyMolecular BiologyEpigeneticsMolecular OncologyTumor MicroenvironmentCancer EpigeneticsCancer EpigenomicsEpigenetic Alterations In CancerEpigenetic HeterogeneityEpigenetic Regulation In CancerTumor Microenvironment InteractionsBreast Cancer EpigeneticsBreast Cancer Resistance MechanismsBreast Cancer Tumor MicroenvironmentEpigenetic DeregulationHypoxic MicroenvironmentImmunosuppressive MicroenvironmentTumor Microenvironment EpigeneticsTumor Microenvironment Hypoxia
Breast cancer comprises a substantial proportion of cancer diagnoses in women and is a primary cause of cancer-related mortality. While hormone-responsive cases generally have a favorable prognosis, the aggressive nature of triple-negative breast cancer presents challenges, with intrinsic resistance to established treatments being a persistent issue. The complexity intensifies with the emergence of acquired resistance, further complicating the management of breast cancer. Epigenetic changes, encompassing DNA methylation, histone and RNA modifications, and non-coding RNAs, are acknowledged as crucial contributors to the heterogeneity of breast cancer. The unique epigenetic landscape harbored by each cellular component within the tumor microenvironment (TME) adds great diversity to the intricate regulations which influence therapeutic responses. The TME, a sophisticated ecosystem of cellular and non-cellular elements interacting with tumor cells, establishes an immunosuppressive microenvironment and fuels processes such as tumor growth, angiogenesis, and extracellular matrix remodeling. These factors contribute to challenging conditions in cancer treatment by fostering a hypoxic environment, inducing metabolic stress, and creating physical barriers to drug delivery. This article delves into the complex connections between breast cancer treatment response, underlying epigenetic changes, and vital interactions within the TME. To restore sensitivity to treatment, it emphasizes the need for combination therapies considering epigenetic changes specific to individual members of the TME. Recognizing the pivotal role of epigenetics in drug resistance and comprehending the specificities of breast TME is essential for devising more effective therapeutic strategies. The development of reliable biomarkers for patient stratification will facilitate tailored and precise treatment approaches.
192
Multilineage Potential of Adult Human Mesenchymal Stem Cells
Mark F. Pittenger, Alastair M. Mackay, Stephen C. Beck et al. · Science · 1999 · 21.1K citations
Hallmarks of Cancer: New Dimensions
Cancer Discovery · 2022 · 9.1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Claudia Allemani, Tomohiro Matsuda, V Di Carlo et al. · The Lancet · 2018 · 6.2K citations · Full text
Medicine, Biostatistics, Oncology +17
THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.
Stephen A. Paget · The Lancet · 1889 · 5.1K citations
Medicine, Cancer Biology, Oncology +12